Medisca News

To protect its valuable rights and ensure that companies compete fairly, Medisca intends to protect its proprietary technologies against competitors’ infringing activities. That global enforcement effort began today with Medisca filing suits against Fagron B.V., HiperScan GmbH, and Gako Deutschland GmbH for infringement of patent number 3,538,071, belonging to the German counterpart of Medisca. The lawsuit was filed in the Munich district court of Germany and requests, as relief, an injunction and monetary remedies.

In 2018, Medisca, a global leader in pharmaceutical compounding and personalized medicine, partnered with the Université Laval Faculty of Medicine located in Quebec, Canada. The commitment included funding the establishment of a Chair in Educational Leadership in Chronic Pain Treatment, donating $500,000 to the initiative. Five years later, Medisca is a proud founding partner of the collaborative success of the Université Laval’s Chair in Educational Leadership in Chronic Pain Treatment-Medisca, Dr. Anne Marie Pinard, MD FRCPC, M.(Ed.), and the Quebec Pain Research Network.

Medisca has announced the expansion of a network of strategic partnerships aimed at securing and stabilizing worldwide access to high quality active pharmaceutical ingredients (APIs) for the preparation of essential medications.

Medisca, a global company offering pharmaceutical compounding products and services, mixing technology, manufacturing, education services and more, announces plans to lease a standalone 60,000 square foot building to consolidate repackaging and distribution operations in Plattsburgh, NY under one roof.

After three successful decades of redefining, shaping, and informing the pharmaceutical compounding industry standard, Medisca is proud to unveil a new global brand identity and corporate positioning that reflects a journey of growth, diversification, and opportunity. Founded in 1989 as a small business with a handful of employees, Medisca has expanded into a global corporation with strategic partners in education, manufacturing, supply chain, and analytical testing that deliver customized solutions with an unwavering commitment to quality and innovation.

On May 31, 2022, Medisca, a global supplier of pharmaceutical compounding products, acquired DIFFUSIMAX® and DIFFUSIMAX®10 liposomal bases (pluronic lecithin organogel or PLO gel), products used for preparing compounded topical formulations, as well as all intellectual property assets of Maxima Pharmaceuticals.